HANSOH PHARMAC. HD-00001 (3KY) — Capital Reinvestment Ratio
HANSOH PHARMAC. HD-00001 (3KY) has a Capital Reinvestment Ratio of 0.07x as of December 2025, meaning it reinvests 0% of its operating cash flow (€6.74 Billion) in capital expenditures (€489.46 Million). For the full cash flow conversion analysis, see 3KY cash flow conversion.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
HANSOH PHARMAC. HD-00001 Capital Reinvestment Ratio (2021–2025)
This chart tracks HANSOH PHARMAC. HD-00001's Capital Reinvestment Ratio across 5 annual periods. Check HANSOH PHARMAC. HD-00001 (3KY) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Annual Capital Reinvestment Ratio for HANSOH PHARMAC. HD-00001 (2021–2025)
Year-by-year Capital Reinvestment Ratio for HANSOH PHARMAC. HD-00001 from 2021 to 2025. See HANSOH PHARMAC. HD-00001 (3KY) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.07x | €6.74 Billion | €489.46 Million | ▼ -46.6% |
| 2024 | 0.14x | €3.86 Billion | €524.93 Million | ▲ +16.8% |
| 2023 | 0.12x | €3.12 Billion | €362.52 Million | ▲ +9.3% |
| 2022 | 0.11x | €2.74 Billion | €291.82 Million | ▼ -42.3% |
| 2021 | 0.18x | €2.58 Billion | €475.44 Million | — |